SynthesisRheumatology international2020
The prevalence of fibromyalgia in axial spondyloarthritis.
Synthesis in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Frequency of irritable bowel syndrome in spondyloarthritis: a multicentric cross-sectional study and meta-analysis.RMD open · 2024Pooled it
- Decoding pain in axial spondyloarthritis: Mechanisms, management, and future directions.Best practice & research. Clinical rheumatology · 2026Review
- Clinical characteristics, comorbidities, and disease activity outcomes in a Saudi Arabian axial spondyloarthritis cohort.Clinical rheumatology · 2026Article
- Sex Differences in Disease Activity Measures in Axial Spondyloarthritis and Their Association with Concomitant Fibromyalgia: A Retrospective Cross-Sectional Analysis of a Saudi Cohort.Journal of clinical medicine · 2026Article
- Why Fibromyalgia Criteria Keep Changing: A Systematic Review of Misclassification, Measurement, and Diagnostic Spillover.Archives of rheumatology · 2026Article
- Sex differences in axial spondyloarthritis: biological mechanisms, clinical phenotypes, and therapeutic implications - a narrative review.Medicine and pharmacy reports · 2026Review
- Axial spondyloarthritis patients with comorbid fibromyalgia feel worse, work less and more often try multiple biological therapies: results from a population-based, cross-sectional study investigating the discriminative capacity of pressure algometry.Rheumatology international · 2026Article
- An Evaluation of Factors Contributing to Primary Nonresponse to Biological Therapy in Patients with Spondyloarthropathy: A Retrospective Cohort Study.Archives of rheumatology · 2026Article
- Clinical characteristics, disease activity and psychosocial burden of axial spondyloarthritis in Jordan: a multicenter cross-sectional study.Scientific reports · 2026Observational
- Inflammation and pain as interconnected targets in axial spondyloarthritis.Nature reviews. Rheumatology · 2026Review
- Assessment of the Concomitance of Fibromyalgia in Patients with Axial Spondyloarthritis and Rheumatoid Arthritis.Archives of rheumatology · 2026Article
- Multidimensional contributors to disease burden in axial spondyloarthritis: role of central sensitization, catastrophizing and sleep disturbance.Advances in rheumatology (London, England) · 2026Article
- Early identification of difficult-to-manage axial spondyloarthritis using machine-learning decision trees.Therapeutic advances in musculoskeletal disease · 2026Article
- Tuberculosis incidence in patients treated with secukinumab - a real-world study in Brazil.Advances in rheumatology (London, England) · 2025Article
- [Digital treatment of fibromyalgia].Zeitschrift fur Rheumatologie · 2025Review
- Pathogenic Crosstalk Between the Peripheral and Central Nervous System in Rheumatic Diseases: Emerging Evidence and Clinical Implications.International journal of molecular sciences · 2025Review
- Fibromyalgia with concomitant immune-mediated rheumatic diseases: an evaluation of clinical characteristics, diagnostic criteria and multimodal treatment outcomes.Advances in rheumatology (London, England) · 2025Article
- Insights into diagnosis and treatment of fibromyalgia among Moroccan rheumatologists: a cross sectional online survey.Reumatologia · 2025Article
- Alterations of the resting-state brain network connectivity and gray matter volume in patients with fibromyalgia in comparison to ankylosing spondylitis.Scientific reports · 2024Article
- Correlations among quality of life, spinal mobility, and disease activity in early-treated axial spondyloarthritis: a single-center cross-sectional study.BMC rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comorbid fibromyalgia, in axial spondyloarthritis (axSpA) has been shown to influence disease activity and function, and quality of life. Although several papers exist, there is no comprehensive and robust systematic review to determine the prevalence of fibromyalgia in this patient group. Thus, the aim of the current study was to provide a definitive estimate of prevalence of fibromyalgia in axSpA, and in axSpA sub-classifications. A systematic literature search was conducted in Ovid MEDLINE, EMBASE, Evidence Based Medicine (EBM), and Cochrane Library, updated to April 2020, combining keywords and relevant MeSH headings, to identify papers reporting the prevalence of fibromyalgia in axSpA, or data from which this could be computed. This was then combined in a meta-analysis with data from the Scotland Registry for Ankylosing Spondylitis (SIRAS), a national axSpA register in Scotland. Data was pooled using random or fixed effects models where heterogeneity was greater or lesser than 75%. From 3401 manuscripts initially identified, 15 papers were included in the final review, plus SIRAS, giving data from 16 separate sources. The prevalence of fibromyalgia, among a total of 5214 patients, was 16.4% (95% CI 12.3-20.5%). Prevalence varied with axSpA sub-classification: ankylosing spondylitis: 13.8% (9.1-18.6%); MRI positive non-radiographic axSpA 20.3% (6.5-34.1%); and 'clinical' disease: 11.1% (6.0-16.2%). Overall, around 1 in 6 patients with axSpA also meet criteria for fibromyalgia. While estimates from individual studies vary, comorbid fibromyalgia represents a considerable burden across all sub-classifications of axSpA. This emphasises that focusing management solely on inflammatory disease in this patient group is unlikely to yield optimal improvements in quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.